A Perspective on the Evolution of Management of Cancer- and Chemotherapy-Induced Anemia

Restricted access

George M. Rodgers, MD, PhD, is Professor of Medicine and Pathology at the University of Utah. His clinical focus in cancer treatment is supportive care, especially use of intravenous iron to optimize anemia management. Dr. Rodgers is a consultant for Amgen.

  • 1

    Henke M, Laszig R, Rube C. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:12551260.

    • Search Google Scholar
    • Export Citation
  • 2

    Bohlius J, Langensiepen S, Schwarzer G. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 2004;3:CD003407.

  • 3

    Leyland-Jones B for the BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459460.

    • Search Google Scholar
    • Export Citation
  • 4

    Auerbach M, Ballard H, Trout JR. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia. J Clin Oncol 2004;22:13011307.

    • Search Google Scholar
    • Export Citation
  • 5

    Bohlius J, Langensiepen S, Schwarzer G. Recombinant human erythropoietin and overall survival in cancer patients; results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;6:489498.

    • Search Google Scholar
    • Export Citation
  • 6

    Bohlius J, Wilson J, Seidenfeld J. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;17:708714.

    • Search Google Scholar
    • Export Citation
  • 7

    Khorana AK, Francis CW, Blumberg N. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:23772381.

    • Search Google Scholar
    • Export Citation
  • 8

    Henry DH, Dahl NV, Auerbach M. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231242.

    • Search Google Scholar
    • Export Citation
  • 9

    Bohlius J, Schmidin K, Brillant C. Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009;3:CD007303.

    • Search Google Scholar
    • Export Citation
  • 10

    Glaspy J, Crawford J, Vansteenkiste J. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301315.

    • Search Google Scholar
    • Export Citation
  • 11

    Gilreath JA, Sageser DS, Jorgenson JA, Rodgers GM. Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients. J Natl Compr Canc Netw 2008;6:577584.

    • Search Google Scholar
    • Export Citation
  • 12

    Gilreath JA, Stenehjem DD, Rodgers GM. Total dose iron dextran infusion in cancer patients: is it saFe2+? J Natl Compr Canc Netw 2012;10: in press.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 200 179 3
PDF Downloads 19 18 1
EPUB Downloads 0 0 0